Z

Zentalis Pharmaceuticals
D

ZNTL

2.14500
USD
-0.10
(-4.24%)
Post Trading·2.14500USD0.00000(0.00%)
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
92,268
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
203,071,256

العنوان: Zentalis Pharmaceuticals

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer(Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.